Trial reportBMC nephrology2025
Using skin biopsies to measure target occupancy of anti-fibrotic molecules: assay development and application for zampilimab in a primate model of chronic kidney disease and in healthy human volunteers.
Trial report in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02879877 (A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects
Who cites it
1 citing paper in PubMed.
- Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants.Clinical pharmacology in drug development · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssessing target engagement (TE) and target occupancy (TO) of novel antifibrotic molecules is challenging, as the target organs are inaccessible. In clinical trials, this often requires biopsies of internal organs, which increases both risk and discomfort for participants. Zampilimab (UCB7858) is a humanized monoclonal antibody that specifically inhibits the extracellular activity of transglutaminase 2 (TG2). Blocking TG2 activity reduces fibrosis in experimental models of chronic kidney disease. Here, a low-risk skin 'biopsy-on-biopsy' approach has been developed as a surrogate to assess TO of zampilimab in the kidney, ahead of further investigation of zampilimab in clinical studies.
methodsA dual-antibody competitive immunofluorescence assay was developed to assess TO of TG2 with zampilimab. A cynomolgus monkey unilateral ureteral obstruction model was used to assess zampilimab TO in the kidney and compare this with TE measured by an in situ TG activity assay. Data were compared with TO in dermal wounds in the same animals. A human skin 'biopsy-on-biopsy' dermal wound approach was developed to induce fibrosis-relevant pathways. Skin sections from healthy volunteers were incubated ex vivo with increasing doses of zampilimab to assess TO.
resultsZampilimab TO in cynomolgus monkey kidney and skin were positively correlated using our immunofluorescence assay, with an inverse correlation between skin TO and kidney TE using our in situ TG activity assay. In the human dermal wound model, maximal TG2 staining was observed on days 4-6 post initial dermal wound (biopsy). TO measurements increased dose-dependently with zampilimab application.
conclusionsZampilimab inhibited TG2 in cynomolgus monkey kidney and skin. Skin is an accessible surrogate tissue to assess kidney TO and predict TE, and our ex vivo model of skin biopsy has potential for application in the development of other antifibrotic therapeutics. A phase I first-in-human study of zampilimab in healthy volunteers (NCT02879877; 26/08/2016) will provide further proof of concept.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.